Company intelligence / Profile preview

Freedom BT

San Francisco, California, United Statessoundcloud.com ↗

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Freedom Biosciences has advanced its lead program, FREE001, to IND approval by the FDA for treatment-resistant depression. The company leverages over 20 years of Yale University research into ketamine’s rapid antidepressant effects. Multiple additional exploratory programs are underway targeting neuropsychiatric conditions using novel formulations of psychedelics and ketamine derivatives.

Therapeutic areas: Psychiatry
Modalities: Small moleculePsychedelic-based therapyKetamine-based therapy
Industry: Biotech

Partnerships

No major pharma partnerships disclosed; licensed technology from Yale University.

Beyond the preview

Go deeper on Freedom BT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Freedom BT.

Explore the full profile